Since the population with comorbid T2DM and HF is growing exponentially, it is important to consider the CV safety and benefits of anti-diabetic drugs. The recent development on the safety, tolerability and cardiovascular-protective effects of SGLT-2 inhibitors has provided new hopes. Moreover, the results from the Phase III DECLARE-TIMI 58 CVOT has been announced and confirmed the well-established safety profile of SGLT-2 inhibitor Dapagliflozin. Astra Zeneca and Docplexus have organized an interactive Webinar on 13 th November 2018 at 3:30 pm .
In this webinar session, Dr. V Mohan will talk about DECLARE: A DEFINING CVOT; WHY NOT SGLT2i NOW and will throw light on the effects of SGLT-2 inhibitors on heart failure incidences in diabetic patients. We invite you to submit your questions which will be answered by the speakers at the end of the session.
